Myocarditis After COVID-19 Vaccination: Risk–Benefit Estimates and Incidence Over Time

Estimating Risk-Benefit and Incidence of Myocarditis Post COVID-19 Vaccination Over Time

September 17, 2023 TruthUSA

The incidence of myocarditis after COVID-19 vaccination has become clearer over time. Presentations, studies, and other data have provided risk-benefit estimates and rates of myocarditis following COVID-19 vaccination. Here are some key findings:

– Risk-Benefit Estimates (June 23, 2021, and July 6, 2021):
– Males 12-17 per million second Pfizer doses:
– Risks: 56-69 myocarditis cases
– Benefits: 5,700 COVID-19 cases, 215 hospitalizations, and two deaths prevented
– Males 18-24 per million second doses:
– Risks: 45-56 myocarditis cases
– Benefits: 12,000 COVID-19 cases, 530 hospitalizations, and three deaths prevented

– Aug. 10, 2021 (CDC):
– Males 18-29 per million second doses:
– Risks: 22-27 myocarditis cases
– Benefits: 300 hospitalizations and three deaths prevented

– Sept. 8, 2021 (US):
– Males 12-15 without medical comorbidities after second Pfizer doses:
– Risks: 162.2 cardiac adverse events per million
– Benefits: 15 hospitalizations per million prevented

– Oct. 26, 2021 (FDA):
– Males 5-11 per million Pfizer doses:
– Risks: 89-179 excess myocarditis cases, 78-156 excess myocarditis hospitalizations
– Benefits: 2,639-57,857 prevented COVID-19 cases, 21-254 prevented COVID-19 hospitalizations, 0-3 prevented COVID-19 deaths

– Females 5-11 per million Pfizer doses:
– Risks: 16-32 excess myocarditis cases, 14-28 excess myocarditis hospitalizations
– Benefits: 45,063 prevented COVID-19 cases, 172 prevented COVID-19 hospitalizations, one prevented COVID-19 death

– In one scenario (scenario 3), excess hospitalizations and ICU stays are higher than prevented hospitalizations and ICU stays.

– Nov. 1, 2021 (England):
– 12-17 over 16 weeks of vaccination:
– Risks: 160 cases of myocarditis
– Benefits: Up to 4,590 hospital admissions and 36 deaths prevented

– April 26, 2022 (FDA):
– Males 16-17 per million Pfizer doses:
– Risks: 98-196 myocarditis cases
– Benefits: 13,577 COVID-19 cases, 127 COVID-19 hospitalizations, and one death prevented

– Aug. 11, 2022 (Australia):
– Males 12-19 per million doses:
– Risks: 146 myocarditis cases
– Benefits: 11,029-110,288 symptomatic cases and 1-11 deaths prevented

– Dec. 5, 2022 (US):
– 18-29:
– Per COVID-19 hospitalization prevented, 18.5 serious adverse events, including 1.5-4.6 myopericarditis cases in males

– June 15, 2023 (FDA):
– Males 18-25 per million Moderna doses:
– Risks: 68-241 myocarditis cases, 58-207 myocarditis hospitalizations
– Benefits: 3,903-219,958 COVID-19 cases, 635-5,957 COVID-19 hospitalizations, 7-63 COVID-19 deaths prevented

Incidence of myocarditis following COVID-19 vaccination has been analyzed based on various health care records. Rates vary across different age and gender groups. It’s important to note that some rates may exclude pericarditis, and “reported cases” are used if based on reports that meet the case definition.

These findings provide valuable information for assessing the risks and benefits of COVID-19 vaccination, helping individuals make informed decisions.

Source link